Lithium nephrotoxicity revisited (original) (raw)

References

1. Belmaker, R. H. Bipolar disorder. N. Engl. J. Med. 351, 476–486 (2004).
   Article CAS PubMed Google Scholar
2. Muller-Oerlinghausen, B., Berghofer, A. & Bauer, M. Bipolar disorder. Lancet 359, 241–247 (2002).
   Article PubMed Google Scholar
3. Freeman, M. P. & Freeman, S. A. Lithium: clinical considerations in internal medicine. Am. J. Med. 119, 478–481 (2006).
   Article CAS PubMed Google Scholar
4. Fornai, F. et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 105, 2052–2057 (2008).
   Article CAS PubMed Google Scholar
5. Martinez, A. & Perez, D. I. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J. Alzheimers Dis. 15, 181–191 (2008).
   Article CAS PubMed Google Scholar
6. Boton, R., Gaviria, M. & Batlle, D. C. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am. J. Kidney Dis. 10, 329–345 (1987).
   Article CAS PubMed Google Scholar
7. Bendz, H., Sjodin, I. & Aurell, M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol. Dial. Transplant. 11, 457–460 (1996).
   Article CAS PubMed Google Scholar
8. Presne, C. et al. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int. 64, 585–592 (2003).
   Article CAS PubMed Google Scholar
9. Stone, K. A. Lithium-induced nephrogenic diabetes insipidus. J. Am. Board Fam. Pract. 12, 43–47 (1999).
   Article CAS PubMed Google Scholar
10. Marples, D., Christensen, S., Christensen, E. I., Ottosen, P. D. & Nielsen, S. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J. Clin. Invest. 95, 1838–1845 (1995).
    Article CAS PubMed Google Scholar
11. Laursen, U. H. et al. Changes of rat kidney AQP2 and Na, K-ATPase mRNA expression in lithium-induced nephrogenic diabetes insipidus. Nephron Exp. Nephrol. 97, e1–e16 (2004).
    Article CAS PubMed Google Scholar
12. Kim, Y. H. et al. Altered expression of renal acid–base transporters in rats with lithium-induced NDI. Am. J. Physiol. Renal Physiol. 285, F1244–F1257 (2003).
    Article CAS PubMed Google Scholar
13. Christensen, B. M. et al. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am. J. Physiol. Cell Physiol. 286, C952–C964 (2004).
    Article CAS PubMed Google Scholar
14. Christensen, B. M., Kim, Y. H., Kwon, T. H. & Nielsen, S. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am. J. Physiol. Renal Physiol. 291, F39–F48 (2006).
    Article CAS PubMed Google Scholar
15. Nielsen, J. et al. Segment-specific ENaC downregulation in kidney of rats with lithium-induced NDI. Am. J. Physiol. Renal Physiol. 285, F1198–F1209 (2003).
    Article CAS PubMed Google Scholar
16. Nielsen, J., Kwon, T. H., Frokiaer, J., Knepper, M. A. & Nielsen, S. Lithium-induced NDI in rats is associated with loss of α-ENaC regulation by aldosterone in CCD. Am. J. Physiol. Renal Physiol. 290, F1222–F1233 (2006).
    Article CAS PubMed Google Scholar
17. Rojek, A. et al. Altered expression of selected genes in kidney of rats with lithium-induced NDI. Am. J. Physiol. Renal Physiol. 288, F1276–F1289 (2005).
    Article CAS PubMed Google Scholar
18. Rao, R. et al. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am. J. Physiol. Renal Physiol. 288, F642–F649 (2005).
    Article CAS PubMed Google Scholar
19. Kotnik, P. et al. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am. J. Physiol. Renal Physiol. 288, F1053–F1068 (2005).
    Article CAS PubMed Google Scholar
20. Li, Y., Shaw, S., Kamsteeg, E. J., Vandewalle, A. & Deen, P. M. Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity. J. Am. Soc. Nephrol. 17, 1063–1072 (2006).
    Article CAS PubMed Google Scholar
21. Bichet, D. G. Lithium, cyclic AMP signaling, A-kinase anchoring proteins, and aquaporin-2. J. Am. Soc. Nephrol. 17, 920–922 (2006).
    Article CAS PubMed Google Scholar
22. Nielsen, J. et al. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc. Natl Acad. Sci. USA 105, 3634–3639 (2008).
    Article CAS PubMed Google Scholar
23. Cohen, P. & Frame, S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2, 769–776 (2001).
    Article CAS PubMed Google Scholar
24. Gould, T. D. & Manji, H. K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 1223–1237 (2005).
    Article CAS PubMed Google Scholar
25. O'Brien, W. T. et al. Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24, 6791–6798 (2004).
    Article CAS PubMed Google Scholar
26. Christensen, B. M., Loffing, J., Hummler, E. & Rossier, B. C. Collecting duct-specific gene inactivation of α ENaC protects mice against lithium-induced nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 17, 295A (2006).
    Google Scholar
27. Bedford, J. J. et al. Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus. Am. J. Physiol. Renal Physiol. 294, F812–F820 (2008).
    Article CAS PubMed Google Scholar
28. Bedford, J. J. et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin. J. Am. Soc. Nephrol. 3, 1324–1331 (2008).
    Article CAS PubMed Google Scholar
29. Batlle, D. C., von Riotte, A. B., Gaviria, M. & Grupp, M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N. Engl. J. Med. 312, 408–414 (1985).
    Article CAS PubMed Google Scholar
30. Leverich, G. S. et al. The poor prognosis of childhood-onset bipolar disorder. J. Pediatr. 150, 485–490 (2007).
    Article PubMed Google Scholar
31. Bendz, H., Aurell, M., Balldin, J., Mathe, A. A. & Sjodin, I. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol. Dial. Transplant. 9, 1250–1254 (1994).
    CAS PubMed Google Scholar
32. Bendz, H., Andersch, S. & Aurell, M. Kidney function in an unselected lithium population. A cross-sectional study. Acta Psychiatr. Scand. 68, 325–334 (1983).
    Article CAS PubMed Google Scholar
33. Lepkifker, E. et al. Renal insufficiency in long-term lithium treatment. J. Clin. Psychiatry 65, 850–856 (2004).
    Article CAS PubMed Google Scholar
34. Bassilios, N. et al. Monitoring of glomerular filtration rate in lithium-treated outpatients—an ambulatory laboratory database surveillance. Nephrol. Dial. Transplant. 23, 562–565 (2008).
    Article PubMed Google Scholar
35. Hestbech, J., Hansen, H. E., Amdisen, A. & Olsen, S. Chronic renal lesions following long-term treatment with lithium. Kidney Int. 12, 205–213 (1977).
    Article CAS PubMed Google Scholar
36. Markowitz, G. S. et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J. Am. Soc. Nephrol. 11, 1439–1448 (2000).
    CAS PubMed Google Scholar
37. Farres, M. T. et al. Chronic lithium nephropathy: MR imaging for diagnosis. Radiology 229, 570–574 (2003).
    Article PubMed Google Scholar
38. Thoma, C. R., Frew, I. J. & Krek, W. The VHL tumor suppressor: riding tandem with GSK3β in primary cilium maintenance. Cell Cycle 6, 1809–1813 (2007).
    Article CAS PubMed Google Scholar
39. Quiroz, J. A., Gould, T. D. & Manji, H. K. Molecular effects of lithium. Mol. Interv. 4, 259–272 (2004).
    Article CAS PubMed Google Scholar
40. Alexander, M. P., Farag, Y. M., Mittal, B. V., Rennke, H. G. & Singh, A. K. Lithium toxicity: a double-edged sword. Kidney Int. 73, 233–237 (2008).
    Article CAS PubMed Google Scholar
41. Bauer, M. Review: lithium reduces relapse rates in people with bipolar disorder. Evid. Based Ment. Health 7, 72 (2004).
    Article PubMed Google Scholar
42. Gonzalez-Pinto, A., Aldama, A., Mosquera, F. & Gonzalez Gomez, C. Epidemiology, diagnosis and management of mixed mania. CNS Drugs 21, 611–626 (2007).
    Article CAS PubMed Google Scholar
43. Garfinkel, P. E., Ezrin, C. & Stancer, H. C. Hypothyroidism and hyperparathyroidism associated with lithium. Lancet 2, 331–332 (1973).
    Article CAS PubMed Google Scholar
44. Christiansen, C., Baastrup, P. C., Lindgreen, P. & Transbol, I. Endocrine effects of lithium: II. 'Primary' hyperparathyroidism. Acta Endocrinol. (Copenh.) 88, 528–534 (1978).
    Article CAS Google Scholar
45. Bendz, H., Sjodin, I., Toss, G. & Berglund, K. Hyperparathyroidism and long-term lithium therapy—a cross-sectional study and the effect of lithium withdrawal. J. Intern. Med. 240, 357–365 (1996).
    Article CAS PubMed Google Scholar
46. Hundley, J. C., Woodrum, D. T., Saunders, B. D., Doherty, G. M. & Gauger, P. G. Revisiting lithium-associated hyperparathyroidism in the era of intraoperative parathyroid hormone monitoring. Surgery 138, 1027–1031 (2005).
    Article PubMed Google Scholar
47. Sloand, J. A. & Shelly, M. A. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am. J. Kidney Dis. 48, 832–837 (2006).
    Article PubMed Google Scholar
48. Gregoor, P. S. & de Jong, G. M. Lithium hypercalcemia, hyperparathyroidism, and cinacalcet. Kidney Int. 71, 470 (2007).
    Article PubMed Google Scholar
49. Sajid-Crockett, S., Singer, F. R. & Hershman, J. M. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 57, 517–521 (2008).
    Article CAS PubMed Google Scholar
50. Shiraki, T., Kohno, K., Saito, D., Takayama, H. & Fujimoto, A. Complete atrioventricular block secondary to lithium therapy. Circ. J. 72, 847–849 (2008).
    Article CAS PubMed Google Scholar
51. Darbar, D., Yang, T., Churchwell, K., Wilde, A. A. & Roden, D. M. Unmasking of Brugada syndrome by lithium. Circulation 112, 1527–1531 (2005).
    Article PubMed Google Scholar

Download references